SynthesisInternational immunopharmacology2021
Effectiveness of corticosteroids to treat severe COVID-19: A systematic review and meta-analysis of prospective studies.
Synthesis in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Effect of anti-inflammatory drugs on the storm of inflammatory factors in respiratory tract infection caused by SARS-CoV-2: an updated meta-analysis.Frontiers in public health · 2023Pooled it
- Pulse versus nonpulse steroid regimens in patients with coronavirus disease 2019: A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization.ImmunoHorizons · 2025Trial
- Impact of vitamin D supplementation on the clinical outcomes of COVID-19 pneumonia patients: a single-center randomized controlled trial.BMC complementary medicine and therapies · 2024Trial
- Review
- Outpatient utilization trend of bronchodilator and anti-inflammatory agents in the pandemic and beyond.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- B cells modulate lung antiviral inflammatory responses via the neurotransmitter acetylcholine.Nature immunology · 2025Article
- Exploring Asthma as a Protective Factor in COVID-19 Outcomes.International journal of molecular sciences · 2025Review
- Continuous glucose monitoring profile in COVID-19 patients with and without diabetes receiving methylprednisolone.Endocrine · 2024Article
- Comparative analysis of COVID-19-associated venous thromboembolism outcomes: evolution from 2020 to 2021-2022.Journal of thrombosis and thrombolysis · 2024Article
- COVID-19 and Cancer Care: A Review and Practical Guide to Caring for Cancer Patients in the Era of COVID-19.Current oncology (Toronto, Ont.) · 2024Review
- Investigation of risk factors for invasive pulmonary aspergillosis among patients with COVID-19.Scientific reports · 2024Article
- Article
- ERS International Congress 2023: highlights from the Respiratory Clinical Care and Physiology Assembly.ERJ open research · 2024Article
- Adherence to application technique of inhaled corticosteroid in patients with asthma and COVID-19 improves outcomes.BMJ open respiratory research · 2024Article
- Serum beta2-microglobulin and peripheral blood eosinophils for the assessment of severity and prognosis with omicron variant COVID-19 infection.Frontiers in molecular biosciences · 2024Article
- COVID-19 hip fracture outcomes: The role of Ct values and D-dimer levels?Journal of orthopaedic translation · 2023Article
- Acute Necrotizing Encephalopathy in Adult Patients With COVID-19: A Systematic Review of Case Reports and Case Series.Journal of clinical neurology (Seoul, Korea) · 2023Article
- Incidence and Impact of Acute Pericarditis in Hospitalized Patients With COVID-19.Journal of the American Heart Association · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the effects of corticosteroid therapy for patients with severe coronavirus disease 2019 (COVID-19).
methodsWe comprehensively searched articles published in the Cochrane Library, PubMed, Embase, China Biology Medicine (CBM), China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases from January 1, 2019, to March 20, 2021.
resultsA total of 6771 patients from eight prospective studies were included in our meta-analysis. The results showed that corticosteroid therapy was associated with lower mortality in severe COVID-19 (OR = 0.70, 95% CI = 0.54-0.92, P = 0.009; I
conclusionsIn this meta-analysis, evidence based on seven randomized controlled trials and one prospective cohort study indicates that corticosteroid therapy was associated with a reduction in the mortality of severe COVID-19, especially when administered at an earlier time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.